# EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

> **NCT06525298** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eisbach Bio GmbH** · enrollment: 144 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Homologous Recombination Deficiency
- HRR Deficiency

## Interventions

- **DRUG:** EIS-12656
- **DRUG:** Olaparib
- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT06525298
- **Lead sponsor:** Eisbach Bio GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525298, "EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06525298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*